Abstract
AbstractThe hit-to-lead process makes the physicochemical properties of the hit molecules that show the desired type of activity obtained in the screening assay more drug-like. Deep learning-based molecular generative models are expected to contribute to the hit-to-lead process. The simplified molecular input line entry system (SMILES), which is a string of alphanumeric characters representing the chemical structure of a molecule, is one of the most commonly used representations of molecules, and molecular generative models based on SMILES have achieved significant success. However, in contrast to molecular graphs, during the process of generation, SMILES are not considered as valid SMILES. Further, it is quite difficult to generate molecules starting from a certain molecule, thus making it difficult to apply SMILES to the hit-to-lead process. In this study, we have developed a SMILES-based generative model that can be generated starting from a certain molecule. This method generates partial SMILES and inserts it into the original SMILES using Monte Carlo Tree Search and a Recurrent Neural Network. We validated our method using a molecule dataset obtained from the ZINC database and successfully generated molecules that were both well optimized for the objectives of the quantitative estimate of drug-likeness (QED) and penalized octanol-water partition coefficient (PLogP) optimization. The source code is available at https://github.com/sekijima-lab/mermaid.
Funder
japan agency for medical research and development
japan society for the promotion of science
Publisher
Springer Science and Business Media LLC
Subject
Library and Information Sciences,Computer Graphics and Computer-Aided Design,Physical and Theoretical Chemistry,Computer Science Applications
Reference37 articles.
1. PhRMA: Biopharmaceuticals in perspective summer 2019 (2019). https://www.phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/P-R/PhRMA_2019_ChartPack_Final.pdf (visited: 2021-3-22)
2. Mullard A (2014) New drugs cost US $2.6 billion to develop. Nat Rev Drug Discov 13(12):877
3. Varma H, Lo D, Stockwell B (2010) High-throughput and high-content screening for huntington’s disease therapeutics. In: Neurobiology of Huntington’s Disease. CRC Press, Amsterdam; pp. 121–14. https://doi.org/10.1201/ebk0849390005-c5
4. Schneider G (2010) Virtual screening: an endless staircase? Nat Rev Drug Discov 9(4):273–276. https://doi.org/10.1038/nrd3139
5. Chiba S, Ikeda K, Ishida T, Gromiha MM, Taguchi Y, Iwadate M, Umeyama H, Hsin K-Y, Kitano H, Yamamoto K, Sugaya N, Kato K, Okuno T, Chikenji G, Mochizuki M, Yasuo N, Yoshino R, Yanagisawa K, Ban T, Teramoto R, Ramakrishnan C, Thangakani AM, Velmurugan D, Prathipati P, Ito J, Tsuchiya Y, Mizuguchi K, Honma T, Sekijima M (2015) Identification of potential inhibitors based on compound proposal contest: tyrosine-protein kinase Yes as a target. Sci Rep 5:17209
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献